CVE-2025-60298

MEDIUM
Published Oct 8, 2025 Modified Oct 10, 2025 CWE-79

Description

Novel-Plus up to 5.2.4 was discovered to contain a Stored Cross-Site Scripting (XSS) vulnerability via the /author/updateIndexName endpoint. This vulnerability allows authenticated attackers to inject malicious JavaScript code through the indexName parameter, which gets stored in the database and executed when other users view the affected book chapter.

Is your site exposed to CVE-2025-60298?

Run a free security scan — no signup, results in seconds.

CVSS v3.1 Score

5.4
MEDIUM
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N

Weakness Type (CWE)

CWE-79 Cross-site Scripting (XSS)

Affected Products

Vendor Product
xxyopen novel-plus

References

Frequently Asked Questions

What is CVE-2025-60298? +
Novel-Plus up to 5.2.4 was discovered to contain a Stored Cross-Site Scripting (XSS) vulnerability via the /author/updateIndexName endpoint. This vulnerability allows authenticated attackers to inject malicious JavaScript code through the indexName parameter, which gets stored in the database and executed when other users view the affected book chapter. It has a CVSS v3.1 base score of 5.4 (MEDIUM).
How severe is CVE-2025-60298? +
CVE-2025-60298 has a CVSS v3.1 score of 5.4 out of 10, rated MEDIUM. This is a medium-severity vulnerability that should be remediated as part of regular maintenance.
What products are affected by CVE-2025-60298? +
CVE-2025-60298 affects products from xxyopen, specifically: novel-plus. Check the affected products table above for specific version ranges.
How do I check if I'm vulnerable to CVE-2025-60298? +
You can use Secably's free Website Scanner to check your website for known vulnerabilities. For infrastructure scanning, use the Port Scanner to identify exposed services that may be affected. Check the vendor advisories linked above for specific patch and version information.

Related Vulnerabilities

Don't wait for an exploit

Scan your website for vulnerabilities like CVE-2025-60298 — free, no signup required.